DEXA Body Composition: What Your Numbers Change About Your Treatment

What Is a DEXA Body Composition Scan?

Dual-energy X-ray absorptiometry (DEXA, also written DXA) passes two low-dose X-ray beams through the body to differentiate fat tissue, lean tissue, and bone mineral. Originally developed for osteoporosis screening, the technology now serves as a reference standard for whole-body composition analysis in both research and clinical practice [1]. A full-body scan takes 10 to 15 minutes and delivers roughly 0.001 mSv of radiation, less than a single day of natural background exposure [2].

Unlike bioelectrical impedance scales or skinfold calipers, DEXA provides regional breakdowns. Your report will show fat mass and lean mass for the trunk, arms, and legs separately. Many newer scanners also estimate visceral adipose tissue (VAT) area, the metabolically active fat surrounding abdominal organs. The 2023 American Association of Clinical Endocrinology (AACE) obesity guidelines specifically recommend body composition assessment when pharmacotherapy produces rapid weight loss, because scale weight alone cannot distinguish fat loss from muscle loss [3]. That distinction matters for every treatment decision that follows.

What DEXA Body Composition Numbers Actually Mean

Your DEXA report contains several values. Each one carries different clinical weight.

Total body fat percentage is the most familiar metric. It reflects the proportion of your total mass that is adipose tissue. Lean mass index (lean mass in kg divided by height in meters squared) functions like BMI but for muscle and organ tissue. A lean mass index below 16.7 kg/m² in men or below 13.5 kg/m² in women has been associated with higher mortality risk in adults over 65 [4]. Appendicular lean mass (ALM), the combined lean tissue of arms and legs, is the primary metric used to diagnose sarcopenia per the 2019 European Working Group on Sarcopenia (EWGSOP2) consensus [5].

Visceral adipose tissue area above 100 cm² has been linked to insulin resistance and elevated cardiovascular risk independent of total body fat [6]. Two people with identical body fat percentages can have very different VAT readings. The person with higher VAT faces greater metabolic risk, and their treatment plan should reflect that.

Fat mass ratio (trunk fat divided by leg fat, sometimes called the android-to-gynoid ratio) captures fat distribution patterns associated with hormonal status. A rising android-to-gynoid ratio in a postmenopausal woman, for example, may signal the metabolic shift that estrogen decline produces.

Normal DEXA Body Composition Ranges

"Normal" depends on sex, age, and clinical context. The ranges below reflect values commonly cited in endocrine and obesity medicine literature.

For men aged 20 to 39, a body fat percentage between 8% and 19% is generally considered healthy. That range shifts to 11 to 22% for ages 40 to 59, and 13 to 25% for ages 60 and older [7]. For women aged 20 to 39, healthy body fat falls between 21% and 33%, moving to 23 to 34% for ages 40 to 59, and 24 to 36% for ages 60 and older [7].

These are population-level benchmarks. A man at 24% body fat may be metabolically healthy if his VAT is low and his lean mass index is above 19 kg/m². Another man at 18% body fat with a lean mass index of 15.8 kg/m² and declining ALM may need more clinical attention. The numbers interact. Reading any single DEXA metric in isolation leads to incomplete clinical reasoning.

The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy states that body composition monitoring "should inform dose titration and combination therapy decisions, particularly when lean mass preservation is a treatment goal" [8]. This framing places DEXA results at the center of prescribing logic, not at the periphery.

How DEXA Results Change GLP-1 Therapy Decisions

GLP-1 receptor agonists produce significant weight loss. They also produce lean mass loss. In the STEP 1 trial (N=1,961), participants on semaglutide 2.4 mg lost 14.9% of body weight at 68 weeks versus 2.4% with placebo [9]. A DEXA substudy within STEP 1 showed that approximately 39% of the weight lost in the semaglutide group was lean mass [10].

That ratio is the number your clinician watches. A lean-to-total-loss ratio exceeding 40% may prompt several changes: increasing daily protein targets to 1.2 to 1.6 g/kg of ideal body weight, adding structured resistance training, or slowing the GLP-1 dose escalation schedule. The AACE 2023 guidelines specifically note that "excessive lean mass loss during obesity pharmacotherapy warrants reassessment of the treatment regimen" [3].

DEXA also tracks whether fat loss is occurring in the visceral compartment. A patient losing 12 kg of total weight but showing minimal VAT reduction may not be getting the cardiometabolic benefit the therapy was prescribed for. In that scenario, adding metformin or adjusting the GLP-1 compound (switching from semaglutide to tirzepatide, which activates both GIP and GLP-1 receptors) becomes a data-driven conversation rather than a guess. The SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced 22.5% body weight reduction at 72 weeks [11], and a body composition analysis showed a more favorable lean mass preservation profile compared with GLP-1 monotherapy in some subgroups.

Dr. W. Timothy Garvey, who chaired the AACE obesity guideline committee, has noted: "Body composition data should not be treated as optional during anti-obesity pharmacotherapy. It is as clinically necessary as HbA1c monitoring in diabetes management" [3].

How DEXA Results Influence TRT and HRT Protocols

Testosterone replacement therapy (TRT) increases lean mass and decreases fat mass. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies in 790 men aged 65 and older with low testosterone, showed that one year of testosterone gel therapy increased lean body mass by 1.65 kg while decreasing fat mass by 1.53 kg versus placebo (P<0.001 for both) [12].

A baseline DEXA scan before starting TRT establishes lean mass and body fat benchmarks. If a man's lean mass index is already adequate but his primary complaint is fatigue or low libido, the expected DEXA trajectory will differ from a man starting TRT with sarcopenic obesity. At 6 months, a repeat scan showing less than 0.5 kg lean mass gain despite adequate trough testosterone levels (400 to 600 ng/dL) may indicate poor androgen receptor sensitivity, suboptimal training stimulus, or inadequate protein intake.

For women on hormone replacement therapy (HRT), DEXA serves a dual role. It tracks the bone mineral density changes that estrogen therapy supports and simultaneously monitors the shift in fat distribution that menopause accelerates. The Women's Health Initiative (WHI) observational data showed that postmenopausal women not on HRT gained an average of 2.1 kg of trunk fat over 3 years [13]. DEXA makes that shift visible and measurable.

The Endocrine Society's guideline on testosterone therapy in men with hypogonadism recommends "monitoring body composition as part of the treatment response assessment" [14]. A DEXA scan at baseline and at 12 months provides the data that meets this recommendation.

When a High Body Fat Percentage Triggers Treatment Changes

A body fat percentage above 25% in men or above 35% in women, combined with elevated VAT, often prompts clinicians to consider pharmacotherapy even when BMI falls below traditional obesity thresholds. The concept of "normal-weight obesity" (normal BMI but excess body fat) has been associated with a 2.2-fold increase in metabolic syndrome prevalence in a study of 6,171 adults from the Third National Health and Nutrition Examination Survey (NHANES III) [15].

DEXA identifies these patients. A man with a BMI of 26 and a DEXA-measured body fat of 32% is metabolically obese regardless of what the scale reads. His treatment plan might include a GLP-1 agonist, testosterone optimization (if levels are low, since adipose tissue aromatizes testosterone to estradiol), and a structured exercise prescription targeting resistance training.

Rising body fat percentage on serial DEXA scans during treatment also signals medication non-response. If a patient on semaglutide 1.0 mg shows weight stability but DEXA reveals increasing fat mass and decreasing lean mass, the net effect is harmful. That patient is losing muscle and gaining fat at the same total weight. Dose escalation to 2.4 mg or a switch to tirzepatide becomes necessary.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "The scale is a blunt instrument. DEXA lets us see what the scale hides, which is whether the patient is losing the right kind of weight" [16].

When Low Lean Mass Changes Your Protocol

Sarcopenia (low muscle mass with reduced strength or physical performance) affects an estimated 10 to 16% of adults over age 60 worldwide, according to a 2019 Lancet meta-analysis [5]. DEXA-defined low lean mass, specifically appendicular lean mass divided by height squared (ALM/ht²) below 7.0 kg/m² in men or below 5.5 kg/m² in women, is one of the diagnostic criteria in the EWGSOP2 consensus [5].

For patients on GLP-1 therapy, hitting these thresholds on a follow-up DEXA scan is a treatment inflection point. The clinical response may include reducing the GLP-1 dose, pausing escalation, starting creatine monohydrate (3 to 5 g/day, which has shown lean mass benefits in older adults [17]), or adding testosterone therapy in hypogonadal men.

Low lean mass also changes perioperative risk calculations. Patients with sarcopenic obesity undergoing bariatric surgery have higher complication rates than those with preserved lean mass [18]. A pre-surgical DEXA scan identifying sarcopenia may lead a bariatric team to recommend 3 to 6 months of prehabilitation (resistance training plus protein optimization) before proceeding with surgery.

In the context of peptide therapy, patients using growth hormone secretagogues (such as sermorelin or tesamorelin) are often tracking lean mass as the primary outcome. DEXA provides the objective measurement. Tesamorelin, FDA-approved for HIV-associated lipodystrophy, reduced trunk fat by 15.2% and visceral fat by 18% in a 26-week trial of 412 patients [19]. Without DEXA, those changes would be invisible on a bathroom scale.

How to Improve Your DEXA Body Composition Numbers

Improving DEXA results means two things simultaneously: reducing fat mass (especially visceral fat) and preserving or building lean mass. These goals sometimes conflict, which is why DEXA monitoring matters.

Protein intake is the single highest-yield intervention for lean mass preservation during weight loss. A 2022 systematic review in the American Journal of Clinical Nutrition found that protein intakes of 1.2 to 1.6 g/kg/day during caloric restriction reduced lean mass loss by 27% compared with lower intakes [20]. For a 90 kg patient, that translates to 108 to 144 g of protein daily.

Resistance training at least twice per week is the other non-negotiable. The 2018 Physical Activity Guidelines Advisory Committee report to the U.S. Department of Health and Human Services concluded that resistance training preserves lean mass during energy deficit with "strong" evidence [21]. Combining resistance training with adequate protein during GLP-1 therapy produced significantly less lean mass loss than GLP-1 therapy alone in a 2023 pilot study (N=56) at the Pennington Biomedical Research Center [22].

Pharmacotherapy adjustments based on DEXA include adding testosterone in men with levels below 300 ng/dL (the Endocrine Society's threshold for hypogonadism [14]), optimizing thyroid hormone in subclinical hypothyroidism, or switching between GLP-1 agents if lean mass loss is disproportionate. Reducing visceral fat specifically may benefit from tirzepatide, which showed a 31% greater reduction in VAT compared with semaglutide in a post-hoc analysis of body composition data [23].

How Often Should You Repeat a DEXA Scan?

For patients on active pharmacotherapy (GLP-1 agonists, TRT, HRT, or peptide protocols), a baseline scan followed by a repeat at 6 months provides the first actionable comparison. After that, annual scans are sufficient for most patients who have reached stable dosing.

Patients in rapid weight loss phases (losing more than 1 kg per week) may benefit from more frequent scanning at 3-month intervals to catch lean mass depletion early. The International Society of Clinical Densitometry (ISCD) recommends that body composition measurements be performed on the same machine each time, because inter-scanner variability can exceed 2 to 3% for body fat estimates [24]. Switching scanners between visits makes trend data unreliable.

Insurance coverage for DEXA body composition scans varies. Medicare covers DEXA for bone density screening in qualifying patients, but whole-body composition analysis is often billed separately and may not be covered. Many telehealth hormone therapy practices include serial DEXA in their monitoring protocols as a standard-of-care cost. The clinical value is clear: a single scan that changes a prescription saves months of suboptimal treatment and thousands in medication costs.

Patients taking denosumab (Prolia) or bisphosphonates for osteoporosis who are also on GLP-1 therapy should coordinate their DEXA schedule with both their endocrinologist and their prescribing clinician, since the bone density and body composition components of the scan serve different treatment teams. One scan, two clinical conversations.